

PRELIMINARY PROGRAMME



Biofit

FOSTERING
INNOVATION
& TRANSFER

The leading European partnering event
for early-stage innovations and seed
investment in the Life Sciences field

7TH
edition

DECEMBER
4TH & 5TH
2018

LILLE
France




www.biofit-event.com

 @BIOFIT_EVENT

BIOFIT AT A GLANCE

BioFIT is both the leading partnering event in Europe for technology transfer, academia-industry collaborations, early-stage innovations and the European marketplace for pre-seed, seed and Series A investment in the Life Sciences field.



80
speakers

100
exhibitors

THE SPONSORS

GOLD SPONSOR



SILVER SPONSOR



BRONZE SPONSORS



CONTRIBUTING SPONSOR



THE ORGANISERS

EURASANTE

Eurasanté is an incubator, a technology transfer tool and a cluster manager all at once, in the biotech, medtech, nutrition and healthcare fields in Northern France. It helps French and foreign companies, entrepreneurs, scientists and clinicians with their innovations and development projects.

The regional network includes more than 1,000 companies working in the Life Sciences and Healthcare fields. It enjoys an exceptional location in the heart of Europe (near Paris, London, Brussels...). The Health field in the Hauts-de-France region has a total of 28,000 employees. Eurasanté also promotes the Eurasanté Bio-business Park which hosts 7 hospitals, 4 universities, 7 specialised schools, 170 companies and 50 laboratories.

In addition, Eurasanté organises 4 international partnering events, which aim to increase and improve interactions between academia and the industry.

www.eurasante.com @Eurasante



THE NHL CLUSTER

The Nutrition Health Longevity (NHL) Cluster is a dynamic network that focuses on the primary health issues of today, at the intersection of health, biotechnology and nutrition.

The NHL Cluster aims to connect academia and industry partners around R&D projects, leading to innovative products in the fields of nutrition and health.

The NHL Cluster focuses on the fields of prevention and treatment of lifestyle-related diseases, such as metabolic and cardiovascular pathologies, neurodegenerative diseases and inflammatory bowel diseases. Its goal is to gather and support players from the health and food sectors in designing, developing and financing their future products and processes.

www.nhl-cluster.com @PoleNSL



ALSACE BIOVALLEY

Alsace BioValley is a French competitiveness cluster which has for mission to federate, develop and promote health players through innovation. The priorities of the cluster are Medicine, Medical Technologies and e-Health.

Alsace BioValley actively participates in development projects of the health sector and supports its members in their R&D innovation approaches enabling them to access high national and international added-value expertise (regulatory, clinical studies, etc.). It also contributes to the networking of its members and develops the ecosystem's visibility, in order to boost market access.

Alsace BioValley relies on a dynamic network of French, German and Swiss companies to succeed, as well as leading academic and clinical research, and an integrated network of partners that are key players in innovation.

www.alsace-biovalley.com @AlsaceBiovalley



THE STEERING COMMITTEE

PHARMA, BIOTECH



Cédric Barrière
DIRECTOR, EXTERNAL INNOVATION
ONCOLOGY, EXTERNAL SCIENCE
AND PARTNERING, **SANOFI** (F)



Maria Bobadilla
SENIOR DIRECTOR, EXTENDING
INNOVATION NETWORK,
ROCHE (S)



Adrian Carter
CORPORATE VICE PRESIDENT AND
GLOBAL HEAD OF DISCOVERY
RESEARCH COORDINATION,
BOEHRINGER INGELHEIM (D)



Sami Chtourou
EXECUTIVE VICE PRESIDENT
INNOVATION & SCIENTIFIC
AFFAIRS, **LFB** (F)



Florence Dal Degan
R&D INNOVATION SOURCING
DIRECTOR, **NOVO NORDISK** (D)



Guy Hélin
CEO,
SYNGULON (F)



Stephan Lensky
CHIEF OPERATING AND CHIEF
BUSINESS OFFICE,
EPIMAB BIOTHERAPEUTICS (D)



Sabrina Lesage
STRATEGIC ALLIANCES MANAGER,
PFIZER (F)



Frédéric Scaërou
SENIOR DIRECTOR, HEAD OF
EXTERNAL INNOVATION EUROPE
AND ASIA, **IPSEN INNOVATION** (F)



Nadine Weisslinger-Darmon
MEDICAL DIRECTOR SPECIALTY
PRODUCTS, CLINICAL RESEARCH AND
ACADEMIC ALLIANCES, **GSK** (F)

ACADEMIA, TTOs



Hervé Ansanay
OPERATIONS DIRECTOR,
SATT AXLR (F)



Jürgen Bauer
DEPUTY MANAGING DIRECTOR,
**EMBLEM TECHNOLOGY
TRANSFER** (D)



Garold Breit
DIRECTOR, TECHNOLOGY
BUSINESS DEVELOPMENT,
CITY OF CHARLESTON (US)



Nicolas Carboni
PRESIDENT,
SATT CONECTUS ALSACE (F)



Jean-Luc Chagnaud
HEALTHCARE BUSINESS
DEVELOPMENT MANAGER
& INTELLECTUAL PROPERTY
MANAGER, **AQUITAINE SCIENCE
TRANSFERT** (F)



Anthony Daccache
BUSINESS DEVELOPER,
SATT NORD (F)



Lilla Farkas
HEAD, OFFICE OF THE MANAGING
DIRECTOR, RESEARCH COORDINATOR,
**MPI-CBG, MAX PLANCK INSTITUTE
OF MOLECULAR CELL BIOLOGY
AND GENETICS** (D)



Esther Lange
INDUSTRY LIAISON MANAGER,
ASCENION (D)

INVESTORS



Franck Hensel
SENIOR INVESTMENT MANAGER,
HIGH-TECH GRÜNDERFONDS (D)



Sara Nunez-Garcia
BIOTECH INVESTOR, FORMERLY
PRINCIPAL WITH SOFINNOVA PARTNERS (F)



Lotfi Yelles Chaouche
PARTNER,
THEODORUS FUND (D)



Zhizhong Yao
ASSOCIATE, CAPITAL FUNDS,
SOFINNOVA PARTNERS (F)

ASSOCIATIONS, CLUSTERS & LAW FIRMS



Barbara Freischem
MANAGING DIRECTOR,
**EBC -EUROPEAN
BIOPHARMACEUTICAL ENTERPRISES** (D)



Yohan Grosjean
COMMUNICATION OFFICER,
**AFSSI - THE FRENCH ASSOCIATION
OF OUTSOURCING AND
INNOVATIVE COMPANIES** (F)



Jean-Louis Hunault
PRESIDENT, **SIMV - THE FRENCH
ASSOCIATION OF THE ANIMAL
HEALTH INDUSTRY** (F)



Marco Pintore
GENERAL MANAGER,
ALSACE BIOVALLEY (F)



Christian Policard
MEMBER OF THE BOARD,
CHAIRMAN OF THE BUSINESS
DEVELOPMENT SUB-COMMITTEE,
FRANCE BIOTECH (F)



Emilie Royère
DIRECTOR,
EUROBIOMED (F)



Cécile Théard-Jallu
PARTNER ATTORNEY, **DE GAULLE
FLEURANCE & ASSOCIÉS** (F)



Etienne Vervaecke
GENERAL MANAGER,
EURASANTE & NHL CLUSTER (F)

PARTNERING

*48 hours to meet your future project partners,
obtain funding and accelerate innovation*

IDENTIFY

today's innovative technologies, collaborations and licensing opportunities

BENEFIT

from a wide range of attendees (Pharma - Biotech - TTOs - Academics - Investors)

MEET

the most qualified players in the Life Sciences field

DEVELOP

new collaborations and partnerships

WHO WILL YOU MEET?



30% TTOs, Research institutions, Academics



20% Pharma & Diagnostic companies



20% Emerging Biotech companies



15% Preclinical CROs



10% Pre-seed, seed and Series A investors



5% Professional services, consulting and law firms

The partnering platform at BioFIT is powered by **partneringONE®**

a service of **EBDGROUP**

PITCH SESSIONS

The early-stage innovations you need

The BioFIT presentation sessions offer the opportunity to detect the most innovative and promising start-ups, R&D projects and licensing opportunities in order to foster partnerships and business development in the Life Sciences field.

Start-up Slams

- The Start-up Slams are dedicated to **entrepreneurs** who have created an innovative start-up company (**from creation up to Series A**).
- Selected applicants will have the opportunity to present their project in front of potential partners and investors during BioFIT.
- A jury composed of pharmaceutical experts and investors will give the presenters feedback and advice («speed-mentoring»).
- The most innovative start-up will be given an award by BioFIT's jury.

Licensing Opportunity Presentations

- The Licensing Opportunity Presentations are dedicated to **TTOs, universities** or related structures that have **ready-to-be-licensed technologies**.
- The selected candidates will have the opportunity to present their out-licensing technologies in front of potential industry partners during BioFIT.



Apply



**Be selected
by a jury of
experts**



**Pitch
during BioFIT
2018**



IDENTIFICATION OF WOULD-BE CEOs

Are you a bioentrepreneur seeking a project? Or do you have projects seeking a CEO?


BioFIT is pleased to announce the organisation of a "Would-be CEOs Networking Lunch" on the 2nd day of BioFIT (December 5th).

As talented CEOs are so much sought-after by so many stakeholders of the biotech industry, to both launch and drive new companies to success, this "Would-be CEOs Networking Lunch" will bring together representatives of emerging start-ups, technology transfer offices, incubators and investing networks as well as CEOs and would-be CEOs to address this crucial issue.

Please note that would-be CEOs can also be identified through the BioFIT partnering platform.

Any bioentrepreneur looking for a project to get involved in is welcome to join BioFIT and particularly this "Would-be CEOs Networking Lunch". Any incubator or tech transfer entity looking for an entrepreneur to lead their start-up launch projects is also welcome to join.

With the support of:



CONFERENCE PROGRAMME



TRACK 1

***Best practices in academia-industry
R&D collaborations***



TRACK 2

***Nurturing and licensing
early-stage assets***



TRACK 3

***Early-stage innovation:
Identify the right funding sources***

PLENARY SESSION

4TH DEC. 11.30 AM - 1.00 PM

SEED FUNDS CROSSING BORDERS: HOW FAR AND HOW FAST IS THE EARLY-STAGE INVESTMENT MARKET IN BIOTECH GLOBALISING?

The early-stage investment actors can be seen as traditionally geographically anchored, but now seed and Series A early-stage investors tend to invest in more diverse geographic areas. Where does the money come from? How far is this evolution towards more global funds going? How fast is it going in the investment community? Will it make the investors more willing to take risks, will it change the risk landscape? Isn't there an ill-balance today between the geographical origin of investment capabilities and the areas that are crawling with projects needing equity investment?

CONFERENCE PROGRAMME



TRACK 1

Best practices in academia-industry R&D collaborations

4TH DEC. 9.30 - 11.00 AM

ARTIFICIAL INTELLIGENCE TO SPEED UP DRUG DISCOVERY: THE REVOLUTIONARY ROAD TO ADVANCING INNOVATION

Companies are now using machine learning in highly specific ways to streamline and improve many day-to-day biomedical research tasks. The use of AI has shifted from generalist tasks to purpose-built tools with numerous applications to speed up drug discovery at all the different research stages. The panel will address some of the uses of AI, ultimately potentially cutting R&D costs by aggregating and synthesising information, repurposing existing drugs, generating and validating novel drug candidates, designing drugs and preclinical experiments, etc.

4TH DEC. 2.30 - 4.00 PM

BEYOND SHARED R&D MEANS OF PHARMA AND ACADEMIC INSTITUTIONS, COMMON STRATEGIES FOR COLLECTIVE SUCCESS

Beyond sharing physical means, this session focuses on deliberate strategies of the life sciences industry and the academic world to pool R&D resources to address common questions and reach common goals through shared R&D strategies and aligned incentives. We will review some partnerships that have chosen to take a leap forward and collaborate together on scientific projects that they couldn't do on their own.

5TH DEC. 9.00 - 10.30 AM

HOW CAN COMMON PATHWAYS IN HUMAN AND ANIMAL HEALTH SET UP A NEW ERA FOR COLLABORATIONS?

Why should a human-focused biotech company be interested in the animal health industry? Are there common grounds that can lead to more frequent and fruitful collaborations between animal and human health companies in the future? Today, it is obvious that the animal health industry offers a clear value proposition to human biotechnology companies, which can maximise the financial and clinical impact of their assets by leveraging both human and veterinary health. The physio pathological features of several diseases (cancer, osteoarticular affections, infectious diseases, pain...) are progressively understood as at least common between animal and human. This paves the way to innovative products developed under the sign of a so-called comparative medicine. This panel will encourage a provocative, straightforward and realistic discussion on what each side needs from the other to set up mutual beneficial partnerships.

5TH DEC. 11.00 AM - 12.30 PM

PATIENT ORGANISATIONS TO JOIN THE PHARMA-BIOTECH-ACADEMIA TRIO: IS A FOURTH MUSKETEER CALLING FOR A NEW WAY TO MANAGE ALLIANCES?

What are the consequences and benefits of adding patient organisations to existing alliances? How do these collaborations work? How do they create value for the whole life sciences community? What is the actual influence on patients of public/private partnerships? What is the actual involvement of patient organisation in financing the collaborations?

CONFERENCE PROGRAMME



TRACK 2

Nurturing and licensing early-stage assets

4TH DEC. 2.30 - 4.00 PM

WHAT ARE THE RECENT INITIATIVES TO ENSURE MORE MATURE ASSETS OF ACADEMIC ORIGIN?

What are the latest group actions to have been jointly taken by the industry, academic institutions, equity investors, and governmental bodies that take academic-origin assets as early as possible and inject the proper amount of money into them, in order to get the project licensed at the right moment and at the safest possible stage?

5TH DEC. 9.00 - 10.30 AM

WHAT ROLES DO ACADEMIC INSTITUTIONS OR TTOS PLAY AS SHAREHOLDERS IN SPINOFFS?

When spinning out a company, one strategy applied by the university or TTO is to often take an equity position in the start-up. When this happens, how do the university or TTO play their role as a shareholder? Do they keep a close eye on the development of the company and continue to offer active support or do they act more as a sleeping partner? How is the risk measured and what is the exit short-term/long-term strategy chosen by those unusual shareholders?

5TH DEC. 2.00 - 3.30 PM

IS EXTERNALISING THE TECH TRANSFER FUNCTION FOR ACADEMIC INSTITUTIONS A KEY TO SUCCEED?

Technology transfer offices play a central role in the biotech ecosystem, as they are meant to bridge the gap between bench and bedside and succeed in commercialising an academic discovery. As most new biotech start-ups arise out of IP resulting from academic research, the efficiency of this system is of outmost importance. This panel discussion will highlight both successes and limits in that externalisation of tech transfer approach.

5TH DEC. 4.00 - 5.30 PM

UNDER PRESSURE: HOW DOES THE URGE TO BRING RARE DISEASE THERAPIES CREATE A NEW RANGE OF BUSINESS OR COLLABORATIVE MODELS?

Bringing new therapies to treat rare diseases requires more than scientific innovation. Innovation in business models and incubation financing is critical as the need to find ways to cost effectively develop new medication is becoming highly important. Initiatives like collaboration centres and rare disease centres try to take the best of both worlds by implementing multidimensional approaches to address the needs of the rare disease community. In addition to conducting their own research, collaborative models that feature pharmaceutical companies, academic institutions, start-ups and patient groups are now being put in place.

CONFERENCE PROGRAMME



TRACK 3

Early-stage innovation: Identify the right funding sources

4TH DEC. 9.30 - 11.00 AM

AGNOSTIC OR PURE PLAYERS IN THE BIOTECH SECTOR: WHO IS BECOMING PROMINENT IN THE EARLY-STAGE FINANCING ROUNDS?

The seed investment market is comprised of players with varied degrees of specialisation, from totally agnostic players involved in multiple industries, to pure players focusing on specific therapeutic areas. Do most specialised funds attract the more generalist types in the financing rounds? What is the importance of the amount of seed investment today for cross-industry funds, 100% healthcare-oriented funds and pure players in the biotech industry, respectively?

4TH DEC. 4.30 - 6.00 PM

THINKING OF THE EXIT SCENARIO TO SHAPE A BIOTECH START-UP AT ITS FIRST STEPS: WHICH MODEL FOR WHICH TERM OF EXIT?

When creating a biotech start-up, different routes can be taken: The virtual biotech model, the technology platform model, the one single asset company... How do those initial choices influence the exit scenario of the company?

5TH DEC. 11.00 AM - 12.30 PM

ARE IMMUNOTHERAPIES STILL AN INVESTMENT ELDORADO?

Investment in immunotherapy in 2018 is still attractive and sought out; what is its growth potential after several years of being an investment blockbuster? What have been the 2018 investment successes in immunotherapy? Will immunotherapy disrupt the oncology market? Are we at the growth, maturity, or saturation stage when we talk about investing in immunotherapy?

5TH DEC. 2.00 - 3.30 PM

HOW AVAILABLE TO BIOTECH START-UPS HAVE PHILANTHROPIC AND OTHER SOURCES OF SOFT FUNDING BECOME TODAY?

All of these non-dilutive financing sources are becoming increasingly numerous thanks to both the emergence of interest expressed by many trusts and foundations in financing innovative start-ups, and also to the many governmental schemes that are devoted to financing the first steps of biotech start-ups. How do these sources of revenue lead to real leverage effect or create constraints for the companies? What types of constraints do they expose biotech entrepreneurs to?

THE SPEAKERS

Over 70 international speakers will share their vision and experience. Among them:

Adrian Ibrahim,
Head of Business Development and Technology Transfer,
Wellcome Trust Sanger
Institute 🇬🇧

Ajan Reginald,
CEO,
Celixir 🇬🇧

Alain Chevallier,
Life Sciences Partner,
Truffle Capital 🇫🇷

Alastair Kent,
Healthcare Consultant,
Independant 🇬🇧

Andreas L.G Reimann,
Managing Partner, Co-Founder
Admedicum Business for
Patients 🇨🇭

Anjan Aralihalli,
Venture Partner,
CTI Life Sciences Fund 🇮🇳

Bernd Stowasser,
Head Alliance Management
Germany & Global Public
Private Partnerships,
Sanofi 🇩🇪

Bertrand Verwee,
International Health Policy
Leader, Rare Diseases
Roche 🇳🇱

Bram Vanparys,
Partner,
Gimv 🇧🇪

Caroline Barelle,
CEO,
Elasmogen 🇬🇧

Chris Maggos,
Managing Director, Head of
Europe,
LifeSci Advisors 🇬🇧

Dean R. Edelman,
Corporate and Foundation
Relations,
Princeton University, Office
of the Dean for Research 🇺🇸

Einat Zisman,
Independent consultant,
Independent consultant 🇮🇱

Emmet Browne,
CEO,
Nuritas 🇮🇪

Ewa G. Truchanowicz,
Business Engagement
Manager,
University of Birmingham
Enterprise 🇬🇧

Gabor Lamm,
Managing Director,
Emblem Technology Transfer 🇭🇺

George Hoffmann,
Co-founder and CEO,
Network Immunology 🇳🇱

Ian Carter,
Director,
Carter Research Navigation 🇬🇧

Jan Adams,
Managing Director,
EMBL Ventures 🇩🇪

Jean-Charles Brosse,
Partner Healthcare & Life
Sciences,
Positive-Capital 🇫🇷

Jemila Houacine,
Associate,
Medicxi 🇬🇧

Jeroen Bakker,
Senior Associate,
Novo Seeds 🇳🇱

Jonathan Tobin,
Investment Director,
Arix BioScience 🇬🇧

Juan R. Garcia,
CEO and Founder,
BioSeed Capital 🇪🇸

Khatereh Ahmadi,
Executive Director, Oncology
MSD 🇩🇪

Laetitia Gerbe,
Partner for investments in AVF
fund,
Seventure Partners 🇫🇷

Lisa Urquhart,
Editor,
EP Vantage 🇬🇧

Lucie Ellis,
Managing Editor,
In Vivo Pharma Intelligence
| Informa 🇬🇧

Luigi Aurisicchio,
CEO,
Takis Biotech - Evvixax 🇮🇹

Madiha Derouazi,
Founder and CEO,
Amal Therapeutics 🇲🇦

Marco A. Chacón,
AVP Industry Alliances
University of Maryland,
Baltimore 🇺🇸

Mark Heffernan,
CEO,
Stonehaven Incubate 🇮🇪

Mark Krul,
Partner,
Aglaia Biomedical Ventures 🇬🇧

Mathias Schmidt,
CEO,
ArmaGen 🇩🇪

Maya Merrell,
Director Business and
Partnership Development,
Fast Forward LLC 🇺🇸

Melanie Senior,
Healthcare Writer & Analyst,
Pharma Intelligence | Informa 🇬🇧

Michael L. Salgaller,
Supervisor, Invention
Development & Marketing
Unit, Technology Transfer
Center,
NIH 🇺🇸

Michael Motz,
Executive & Entrepreneur,
Netris Pharma 🇩🇪

Mirko Scherer,
Managing Partner and CEO,
TVM Capital China Limited 🇨🇳

Nick Clarke,
Head of UK Academic
Partnerships, External Sciences
& Innovation,
Pfizer WRD 🇬🇧

Noor Shaker,
Co-Founder and CEO,
GTN LTD 🇬🇧

Oliver Gajda,
Executive Director and Founder,
European Crowdfunding
Network 🇩🇪

Olivier Arnaud,
Senior Director - European
Research,
Juvenile Diabetes Research
Foundation 🇫🇷

Pascal Sempé,
Director Consultative Sales,
IBM 🇫🇷

Peter Leonardi,
CEO,
OmniCyte 🇺🇸

Rodolphe Besserve,
Head SuFT Advisory,
Société Générale Corporate
Investments and Banking 🇫🇷

Simon J. Draper,
Co-Founder,
SpyBiotech 🇬🇧

Stephan Lensky,
Chief Operating and Chief
Business Officer,
EpimAb Biotherapeutics 🇮🇱

Steve Nanchen,
Advisor External Innovation,
Elanco R&D 🇨🇭

Steven J. Klein,
VP Business Development,
IRICoR - Institute for Research in
Immunology and Cancer -
Commercialization of Research 🇺🇸

Sven Arnouts,
Business Development Manager,
PROVAXS 🇮🇪

Tiina K. Urv,
Program Director, Office of
Rare Diseases Research,
NIH - NCATS 🇺🇸

Wim Van Camp,
General Manager Technology
Transfer,
Ghent University 🇧🇪

Yann Barrault,
Head of Business Development
& Licensing,
SATT Grand Centre 🇫🇷

Zishan Haroon,
Chairman & General Partner,
Julz Co 🇬🇧

DAY ONE Tuesday, December 4th

	Conferences and roundtable discussions		Pitch sessions
8.30 am 9.30 am	NAME BADGE PICKUP & WELCOME COFFEE		
9.30 am 11.00 am	Agnostic or pure players in the biotech sector: Who is getting prominent in the early-stage financing rounds?	Artificial Intelligence to speed up drug discovery: The revolutionary road to advancing innovation	Licensing Opportunity Presentations
11.00 am 11.30 am	NETWORKING BREAK		
11.30 am 1.00 pm	PLENARY SESSION Seed funds crossing borders: How far and how fast is the early-stage investment market in Biotech globalising?		
1.00 pm 2.30 pm	LUNCH		
2.30 pm 4.00 pm	Beyond shared R&D means of pharma and academic institutions, common strategies for collective success	What are the recent initiatives to ensure more mature academic-origin assets?	Start-up Slams
4.00 pm 4.30 pm	NETWORKING BREAK		
4.30 pm 6.00 pm	Thinking of the exit scenario to shape a biotech start-up at its first steps: Which model for which term of exit?	Licensing Opportunity Presentations	
6.30 pm	BIOPARTY		

One-to-one meetings

FOSTERING
INNOVATION
& TRANSFER

Biofit



DAY TWO Wednesday, December 5th

	Conferences and roundtable discussions	Pitch sessions	One-to-one meetings	
8.30 am 9.00 am	WELCOME COFFEE			
9.00 am 10.30 am	What roles do academic institutions or TTOs play as shareholders in spinoffs?	How can common pathways in human and animal health set up a new era for collaborations?		Start-up Slams
10.30 am 11.00 am	NETWORKING BREAK			
11.00 am 12.30 pm	Are immunotherapies still an investment Eldorado?	Patient organisations to join the pharma-biotech-academia trio: Is a fourth musketeer calling for a new way to manage alliances?		Licensing Opportunity Presentations
12.30 pm 2.00 pm	LUNCH + Would-be CEOs Networking Lunch			
2.00 pm 3.30 pm	How available to biotech start-ups have philanthropic and other sources of soft funding become today?	Is externalising the tech transfer function for academic institutions a key to succeed?		Start-up Slams
3.30 pm 4.00 pm	NETWORKING BREAK			Start-up Slams Award Ceremony
4.00 pm 5.30 pm	Under pressure: How does the urge to bring rare disease therapies create a new range of business or collaborative models?			

FOSTERING INNOVATION & TRANSFER

Biofit



TRACK 1
Best practices in academia-industry R&D collaborations














TRACK 2:
Nurturing and licensing early-stage assets











TRACK 3:
Early-stage innovation: Identify the right funding sources

AGENDA | HOSTED EVENTS

	Dec. 3 rd	Dec. 4 th					
	<div>Boehringer Ingelheim</div> <div>Partnering Day</div>	<div>SMML-E</div> <div>yncréa</div> <div>Event</div>	<div>Egid</div> <div>Symposium</div>	<div>Imode</div> <div>Convention</div>	<div>SIMV</div> <div>R&D dating</div>		
8.30 am	WELCOME	<div>Biofit</div> <div>FOSTERING INNOVATION & TRANSFER</div> <div>One-to-one meetings</div>	WELCOME COFFEE	WELCOME COFFEE			
9.00 am	1:1 Partnering Meetings		Introduction				
9.15 am			Gut-Brain glucose signalling in the control of energy homeostasis	IMODE overall presentation	<div>SIMV R&D DATING FOR ANIMAL HEALTH AND INNOVATION</div>		
9.30 am			Food and type 2 diabetes: Restoring the Milieu Interieur	Electrospinning approach for drug delivery			
10.00 am				Nanostructured materials: The next generation of active stents vessels			
10.30 am			Insights from bariatric surgery	BREAK		<div>SIMV R&D DATING FOR ANIMAL HEALTH AND INNOVATION</div> <div>R&D dating for animal health and innovation</div>	
10.45 am	LUNCH		DRINK	POSTER SESSION	Tissue Engineering approach		
11.00 am					Regenerative medicine approach		
11.30 am					Cardiovascular Disease, Restenosis and Thrombosis		
12.00 pm					LUNCH		
12.30 pm							
1.00 pm	LUNCH						
1.30 pm	1:1 Partnering Meetings and Registration for afternoon sessions	WELCOME	LUNCH				
2.00 pm		WORKSHOP on “Organs on Chip for cell therapy and rugs screening”			Incretins, diabetes and CV disease	<div>Biofit</div> <div>FOSTERING INNOVATION & TRANSFER</div> <div>One-to-one meetings</div>	Animal Health R&D Service Presentations
2.30 pm					Therapeutic potential of multi-incretin therapy — from mice to men		
3.15 pm	Company Presentations	NETWORKING BREAK		Award Ceremony of the AFVAC*			
3.30 pm		ROUND TABLE What curriculum for Research or Education on Digital Systems and Life Science	Best paper award		<div>SIMV R&D DATING FOR ANIMAL HEALTH AND INNOVATION</div> <div>R&D dating for animal health and innovation</div>		
4.00 pm				Presentation of the Yncréa Chair			Conclusion & Invitation to the cheese and wine cocktail
4.30 pm	PRESS CONFERENCE						
4.30 pm	Panel Discussion: Collaborative Research and Partnering with Boehringer Ingelheim						
5.00 pm	NETWORKING RECEPTION						
5.30 pm							
5.45 pm							
6.00 pm		BIOPARTY					

* AFVAC: French Association of Veterinarians for Pets

AGENDA | HOSTED EVENTS

	Dec. 5 th			
	 EDCA EUROPEAN DIAGNOSTIC CLUSTERS ALLIANCE	 R&D dating SIMV FOSTERING INNOVATION & TRANSFER MEDICINE (7 REACT) VETERINARIES	 PATHACOV HUMAN DISEASES DIAGNOSTIC BY VOC ANALYSIS IN BREATH	
9.30 am	 FOSTERING INNOVATION & TRANSFER Biofit One-to-one meetings	 SIMV R&D DATING FOR ANIMAL HEALTH AND INNOVATION	Early diagnosis of human diseases through analysis of VOC in exhaled breath	
10.30 am				
12.30 pm	 FOSTERING INNOVATION & TRANSFER Biofit One-to-one meetings	 SIMV R&D DATING FOR ANIMAL HEALTH AND INNOVATION	R&D dating for animal health and innovation	
1.00 pm				
5.30 pm	 FOSTERING INNOVATION & TRANSFER Biofit One-to-one meetings			

INNOVATION @ BOEHRINGER INGELHEIM

Partnering Day **December 3rd, 2018 | Lille**

Fostering Innovation

Boehringer Ingelheim knows what it takes to be innovative and entrepreneurial. From the small factory in 1885 to today's global pharmaceutical organisation, we know how important it is to nurture and develop emerging science and technology.

Our track record of bringing breakthrough medicines to patients starts with new ideas and new science, and collaborations with external partners play a key role in helping us deliver an innovation-led portfolio. Join us at our partnering day to explore how we can develop the next generation of medicines together.

For more information on our partnering interests please visit:
www.boehringer-ingelheim.com/partnering/interests

Meet our Research and Partnering Teams

9.00 AM - 12.30 PM 1:1 Partnering Meetings

12.30 PM - 1.30 PM Networking Lunch

1.30 PM - 3.30 PM 1:1 Partnering Meetings and Registration for afternoon sessions

3.30 PM - 4.30 PM Company Presentations

4.30 PM - 5.30 PM Panel Discussion: Collaborative Research and Partnering with
Boehringer Ingelheim

5.30 PM - 6.30 PM Networking Reception

Register to attend the event and, if interested, apply for a one-to-one meeting to discuss potential opportunities for partnering with our team.
Deadline to register: November 1st, 2018

Organised by:



R&D DATING FOR ANIMAL HEALTH AND INNOVATION

December 4th & 5th, 2018 | Lille



BioFIT 2018 will host the 4th edition of the "R&D dating for Animal Health and Innovation" business convention, at the French association for the animal healthcare industry (SIMV)'s initiative, on December 4th and 5th, 2018, in Lille.

Today, public-private and private-private partnerships are thought to be the leverage that is needed for innovation. That is why the SIMV launched the "R&D dating for Animal Health and Innovation", which strives to initiate high-level exchanges between research departments of the veterinary medicine and diagnostics industry and public research, as well as with biotechnology companies (start-ups).

By enabling face-to-face encounters, the event will enhance the visibility of cutting-edge research in France and in Europe, encourage investments and lead to therapeutic innovation.

Contact: secretariat@simv.org

Organised by:



 simv.org

EGID SYMPOSIUM



December 4th, 2018 | Lille

5th edition:
THE GUT, INCRETINS, DIABETES

Steering Committee



**Philippe
Froguel**

MD, Ph D, Director of UMR CNRS 8199-University of Lille and Pasteur Institute of Lille, Director of Research Federation 3508 labex EGID and Director of equipex LIGAN Personalized Medicine and Institute of Genomics of Lille



**François
Pattou**

Professor of surgery, University of Lille, CHU Lille Inserm



**Bart
Staels**

Director of UMR1011 Inserm, University of Lille – EGID, CHU Lille, Pasteur Institute of Lille

Programme Overview

Gut-Brain glucose signalling in the control of energy homeostasis

Gilles Mithieux, Director UMR-S1213-UCBL, Director of ALECS, Inserm 1213, Faculty of Medicine Laennec

Food and type 2 diabetes: Restoring the Milieu Interieur

Roy Taylor, Professor of Medicine and Metabolism and Director, Newcastle Magnetic Resonance Centre, Newcastle University

Insights from bariatric surgery

Rachel Batterham, Professor of Obesity, Diabetes and Endocrinology – NIHR Research Professor, Head of UCLH Obesity & Bariatric Services, Head of Center for Obesity Research, Department of Medicine, Rayne Building, University College London

Incretins, diabetes and CV disease

Nikolaus Marx, Professor of Medicine / Cardiology, Head of the Department of Internal Medicine I, University Hospital Aachen

Therapeutic potential of multi-incretin therapy — from mice to men

Aimo Kannt, Head, Comorbidities and Complications of Diabetes, Sanofi Diabetes Research

In partnership with:



SMMIL-E/YNCREA EVENT DIGITAL SYSTEMS & LIFE SCIENCE

Programme December 4th, 2018 | Lille

WORKSHOP ON “ORGANS ON CHIP FOR CELL THERAPY AND DRUGS SCREENING”

Cell fibers for cell therapy and organ on chip application

Pr. Shoji Takeuchi, Institute of Industrial Science, University of Tokyo

Developing Tools to Stem the Illicit Trafficking of Protected Species

Pr. Karl Bohringer, University of Washington, Seattle, USA

Study of the Metastatic Process by 3D Cells Models

Dr. Jean-Louis Viovy, Curie Institute, Paris, France

Biomimetic approaches in Liver Tissue Engineering: Application to drug screening and bioartificial liver

Dr. Cécile Legallais, Laboratory BMBI, UT Compiègne, France

3D cells model for high content drug screening for vascularisation evaluation

Dr. Nathalie Maubon, HCS Pharma, Lille, France

Dr. Fabrice Soncin, LIMMS/CNRS-IIS, Lille, France

Dr. Yukiko Matsunaga, Institute of Industrial Science, University of Tokyo

Round table: What curriculum for Research or Education on Digital Systems and Life Science

Presentation of the Yncréa Chair: Digital Systems and Life Science

Mr. Thierry Occre, General Director, Yncréa ISEN Lille, France and Yncréa Morocco

Dr. Andreas Kaiser, Research and Innovation Director, Yncréa Hauts-de-France, Lille, France

Dr. Dominique Collard, LIMMS/CNRS-IIS, Research Director at CNRS, Chair Director

PRESS CONFERENCE

Organised by:



IMODE

December 4th, 2018 | 9.30 am - 6.00 pm | Lille

IMODE is organising its second annual convention during BioFIT with a morning of conferences and participation in the BioFIT one-to-one meetings during the afternoon.

Conference Programme Overview:

IMODE overall presentation

Pr. Frédéric Affouard, University of Lille, UMET Laboratory, IMODE's coordinator

Electrospinning approach for drug delivery

Dr. Stéphanie Degoutin, University of Lille, UMET Laboratory

Nanostructured materials: The next generation of active stents vessels

Dr. Ariane Boudier, University of Lorraine, Director of CITHEFOR Laboratory

Tissue Engineering approach

Dr. Nicolas L'Heureux, University of Bordeaux, Director of BioTis Laboratory

Regenerative medicine approach

Dr. Laurence Bordenave, CHU Bordeaux, Head of Nuclear Medicine

Cardiovascular Disease, Restenosis and Thrombosis

Dr. Blandine Maurel, CHU Nantes, Vascular surgeon

IMODE is a collaborative research project for multicomponent pharmaceutical products (co-amorphous and co-crystals) and medical devices that are loaded with bioactive molecules. Started in 2016, the IMODE project is funded by the European Interreg 2 Seas programme and co-financed by the European Fund for Regional Development (EFRD).

The project's overall objective is to bring together the specific transdisciplinary skills and experiences of partners (academic research groups, development agencies, SMEs) in order to provide the 2 Seas Area with strategic advantages for innovative pharmaceutical and medical applications. The IMODE project is motivated by an unmet need to develop solutions to addressing societal challenges to improve healthcare and provide novel and effective medication for various cardiovascular or gastro-intestinal conditions that lack or have inadequate treatment, all while keeping medical costs low.

Organised by:



Project partners:



 **project-imode.eu**

EUROPEAN DIAGNOSTIC CLUSTERS ALLIANCE

(EDCA) December 5th, 2018 | 10.30 am - 12.30 pm | Lille

EDCA invites you to a round table during BioFIT to exchange on the hot topic of **the new European In Vitro Diagnostic Regulation**.

About EDCA:

European Diagnostic Clusters Alliance – EDCA is the first European network serving the competitiveness of the medical diagnostic industry. It federates 8 European clusters and counts 350 companies.

The purpose of EDCA is:

- To promote competitiveness of European industry in the area of medical diagnosis. The association will enhance the synergies between academic research, clinical research, health authorities and diagnostic companies;
- To ease the growth of European SMEs in medical diagnostic;
- To promote the development of diagnostic clusters and competitiveness clusters in Europe;
- To promote cooperation between diagnostic clusters (inter-cluster) in order to help build European collaborative projects.

EDCA members:

- BioTurku (Finland)
- BioWales (United Kingdom)
- BioWin (Belgium)
- Eurobiomed (France)
- Heath Capital (Germany)
- Medicen (France)
- The Oxford AHSN (United Kingdom)
- Uppsala Bio (Sweden)



EVENT HOSTED BY  **Biofit**

PATHACOV

December 5th, 2018 | 9.30 am - 1.00 pm | Lille



Head of Project: **Pr. Régis Matran**, Professor of Respiratory Physiology, Lille University Hospital

Early diagnosis of human diseases through analysis of VOC in exhaled breath

The challenge is to develop and implement an innovative methodology in the health field and in particular in the early diagnosis of bronchopulmonary cancers.

The project will enable all populations on both sides of the border, regardless of socio-economic level, to have access to a simple, non-traumatic method for early detection of bronchopulmonary cancer and other human diseases.

Programme Overview:

Introduction to the Interreg France-Wallonia-Vlaanderen Programme

Pathacov Project and patient impact

Specific markers VOC (Volatile Organic Compounds)

Innovative tools for early diagnosis

Project partners:



The leading European partnering event for early-stage innovations and seed investment in the Life Sciences field



JOIN BIOFIT 2018

REGISTRATION FEES

(excl. VAT)

	EARLY BIRD Before June 30 th included	REGULAR FEE From July 1 st until November 4 th included	LATE REGISTRATION From November 5 th
Mature company (> 5 years old)	€ 959	€ 1,199	€ 1,319
Investor (pre-seed, seed or Series A)	€ 959	€ 1,199	€ 1,319
Cluster Association	€ 816	€ 1,019	€ 1,121
TTO Research institution	€ 639	€ 799	€ 879
Emerging company (≤ 5 years old) or SME (≤ 5 employees)	€ 384	€ 479	€ 527
Academic scientist	€ 319	€ 399	€ 439

EXHIBITION FEES (excl. VAT)

Gain visibility by exhibiting at a fully equipped booth within the exhibition area and have your one-to-one meetings at your own stand:

- 6 m² equipped booth - **€ 2,200** (1 partnering pass included)
- 9 m² equipped booth - **€ 3,300** (1 partnering pass included)
- 12 m² equipped booth - **€ 4,400** (1 partnering pass included)
- 18 m² equipped booth - **€ 6,600** (2 partnering passes included)

SPONSORSHIP OPPORTUNITIES (excl. VAT)

Discover the sponsorship opportunities and maximise your presence:



Gold Sponsor
€ 15,000



Silver Sponsor
€ 10,500



Bronze Sponsor
€ 6,000

There are many additional
visibility opportunities, please
contact us for a customised
offer.

SPONSORS & PARTNERS

SPONSORS



SUPPORTERS



MEDIA PARTNERS



EVENT VENUE

Lille Grand Palais
1, boulevard des Cités Unies
59000 Lille - France

www.biofit-event.com

 **@BIOFIT_EVENT**

CONTACTS

GENERAL ENQUIRIES:

Margaux Satola
msatola@eurasante.com
+33 (0)3 59 39 01 82

CONFERENCE PROGRAMME:

Claire Lesnik
clesnik@eurasante.com
+33 (0)3 59 39 01 87

LILLE AND THE HAUTS-DE-FRANCE REGION, A REGION OF EXCELLENCE IN THE HEALTHCARE SECTOR

The Lille Region is the 3rd ranked life sciences cluster in France. The main areas of expertise in the Hauts-de-France region are metabolic diseases, ageing diseases, nutrition and blood related products. The pharma-biotech sector in Northern France enjoys the presence of both big companies (AstraZeneca, Bayer, GSK...), a dense network of innovative start-ups (AlzProtect, ImaBiotech, Innobiochips...) and dynamic mid-size biopharmaceutical companies (Diagast, Genfit, Genoscreen, LFB...).

The pharma-biotech sector in the Hauts-de-France region:

- Export turnover of more than €3 billion
- Regional turnover of €6 billion (11% of the €53 billion national turnover)
- 11,600 jobs (11% of jobs in France in this sector)



Organised by:



In collaboration with:



Institutional partners:

